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Abstract
Background: Lighthouse Trust operates two, public, integrated HIV clinics, Lighthouse (LH) and Martin Preuss Center (MPC),
in Lilongwe, Malawi. Approximately 20% of patients eligible for antiretroviral therapy (ART) do not start ART. We explore
individual and geographic factors that influence whether ART-eligible patients initiate ART.
Methods: Adult patients eligible for ART between 2008–2011 were included. Analysis was stratified by clinic. Using logistic
regression, we evaluated factors associated with initiating ART including gender, age, body mass index (BMI), employment,
tuberculosis (TB), eligible at initial registration, WHO stage, CD4, months in pre-ART care (from initial registration to
eligibility date), and patient neighborhood distance to clinic.
Results: Of 14,216 study patients, 4841 were from LH; 9285 were from MPC. At LH and MPC, respectively, median age was
34.2 and 33.8 years; median BMI was 22.0 and 20.6; and median distance was 5.6 and 4.9 Km. In multivariate models, odds of
starting ART was highest among those older than 35 years and those eligible for ART based on WHO stages 3–4 vs. those in
WHO stages 1–2 with CD4,250. Patients with 1–12 months in pre-ART were at least 11 times more likely to start ART than
peers with less pre-ART time. At LH, living 2.5–5 Km from the clinic increased the likelihood of starting ART over patients
living closer.
Conclusions: Length of the pre-ART period is the most significant predictor of starting ART among eligible patients. Better
understanding of motivation for retention in pre-ART care may reduce attrition along the treatment cascade.
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Introduction
As access to life-sustaining antiretroviral therapy (ART)
increases throughout much of sub-Saharan Africa, attention is
needed to improve quality services throughout the continuum of
HIV-related care, including the period before ART initiation.
Previous studies from sub-Saharan Africa examine loss to follow
up (LTFU) among HIV-infected patients who were not yet eligible
to start ART [1,2,3,4] and factors that influence LTFU after ART
initiation [5,6,7,8,9,10]. However, the period between ART
eligibility and ART initiation, during pre-ART care, is a time of
high vulnerability [11,12]. In sub-Saharan Africa, pre-ART
program attrition or discontinuation of care for any reason
including LTFU and death, ranges from 14%–84% [13],
illustrating a sizeable gap in the continuum of ART services.
Patients who are lost to attrition after becoming eligible may
eventually enter care later and sicker [14,15,16], decreasing the
overall effectiveness, and increasing the costs, of HIV treatment
programs [13]. Hence, greater understanding of the drivers of
attrition during this critical stage would strengthen efforts to retain
patients during this transition.
In Malawi, program attrition across the continuum of HIV-
related care is of concern. By 2011, the Ministry of Health
reported national ART program coverage at 67% [17], indicating
both great progress in ART scale up as well as lingering
weaknesses moving ART-eligible patients into life-long treatment.
National adult HIV prevalence remains high at approximately
12%; the majority of HIV-infected persons seek HIV-related care
at public clinics [17]. Lighthouse Trust, the largest provider of
HIV-related services including ART in Lilongwe, Malawi and a
flagship public provider of HIV-related services [18], runs two
high-burden, integrated ART clinics: Lighthouse clinic (LH) on
the campus of Kamuzu Central Hospital and the Martin Preuss
Center (MPC) on the campus of Bwaila Hospital. Although
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national-level pre-ART attrition is unknown, approximately 20%
of eligible patients do not start ART at LH and MPC, likely
indicative of a similarly sized gap in the continuum of care at other
public clinics.
In this study we explore the individual and geographic factors
that influence whether ART-eligible patients at LH and MPC
initiate ART. Increasing knowledge of the drivers of, and
impediments to, ART initiation among eligible patients will help
inform programmatic and policy efforts to reduce attrition during
this critical period of entry to ART care.
Methods
Ethics Approval
According to the Malawi National Health Science Research
Committee (NHSRC) guidelines, retrospective reviews of existing
programmatic data are exempt from formal consenting proce-
dures. Lighthouse received approval from the NHSRC for this
study in 2011 for analysis of routine programmatic data and
publication of results from operations research.
Study Setting
The Lighthouse Trust partners with both the Malawi Ministry
of Health (MoH) and the District Health Office (DHO) in
Lilongwe to operate two integrated HIV clinics. Lighthouse (LH)
Clinic opened in 2001. The Martin Preuss Center (MPC), located
near the central bus station, opened in Dec 2006 as a purposeful
TB/ART integration site [19]. Combining patients at both clinics,
the Lighthouse Trust is the largest public provider of free ART in
the Central Region with over 22,000 patients in HIV-related care.
From 2008 onwards, both LH and MPC used a real-time,
touchscreen-based electronic data system (EDS) for patient
management which improved clinic performance and reduced
data errors [20]. The EDS collects HIV testing details, residential
location, demographics, and World Health Organization (WHO)
stage at registration. The EDS also includes CD4 test results,
opportunistic infections, reported side effects, and drug dispensing
records. Pre-ART patient information is not stored longitudinally
in the EDS; only registration, demographic, and most recent
eligibility-relevant information is retained.
Figure 1. Flow chart of patient population characteristics retained in the study.
doi:10.1371/journal.pone.0050871.g001
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Table 1. Descriptive statistics of all eligible patients, by clinic.
Lighthouse MPC








Mean (SD) 35.5 (9.3) 35.2 (9.4)










Mean (SD) 22.6 (4.0) 21.0 (3.5)
Median (IQR) 22.0 (20.0–24.4) 20.6 (18.8–22.7)
CD4 count (cell/mm3) 2328 2931
Mean (SD) 155.8 (102.2) 150.0 (88.9)





TB diagnosed at eligibility***
Yes 4.7 24.4
No 95.3 75.6




Mean (SD) 13.1 (32.4) 3.88 (12.9)












Distance from clinic (Km) 4138 8447
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Although the MoH revised national ART guidelines in June,
2011 [21], Malawi’s 2008 National ART guidelines used at
Lighthouse and all ART clinics defined ART eligibility for adults
as meeting one of three criteria: 1) WHO stage 1 or 2 in
combination with CD4 cell count of less than 250 cell/mm3; 2)
WHO stage 3; or 3) WHO stage 4 [22]. Pre-ART patients, HIV-
infected individuals who have not started ART, are reviewed every
2 months to provide co-trimoxazole therapy (CPT) and to evaluate
for any potential stage 3 or 4 defining conditions. Pre-ART
patients should also undergo routine CD4 testing at 6-month
intervals to monitor for ART eligibility; however, weaknesses in
the laboratory system and problems with CD4 machines may
delay or prevent CD4 testing or results provision. Also, patients
who have an infection or condition indicative of a WHO 3 or
WHO 4 condition, including TB, are immediately eligible for
ART and may not have a CD4 test ordered or results recorded.
Pre-ART patients may seek care between visits if they are sick.
Clinical procedures and hours of operation (Monday to Friday
7:30am24:30pm, Saturday from 8am to 12pm) are identical at
MPC and LH. At the first clinic visit and all subsequent pre-ART
visits, patients are clinically staged and those with Stage 3 or 4
conditions are immediately informed of their ART eligibility by a
clinician. Those who are stage 1 or 2 typically undergo CD4
testing to determine eligibility and are scheduled to return in 2
weeks for the result. Before an individual can begin ART, they are
required to attend an ART education session with a guardian,
usually a family member or friend. Eligible patients may start ART
on the same day as the initial clinic visit or on the day of receiving
their CD4 result if education and guardian requirements are met.
Pregnant women are eligible for expedited start procedures [23]
and were, therefore, excluded. Transfer patients were excluded
due to incomplete data on eligibility criteria or pre-ART care prior
to transfer.
Independent Variables and Covariate Definitions
Adult patients (.15 years) included in the study were informed
of their eligibility for ART during a clinic visit between January 1,
2008–June 30, 2011. WHO stage 3 and 4 patients would be
eligible and informed at a single visit; patients eligible by CD4
would require an additional visit before being informed. The
binary outcome of interest was ART start or not as defined by the
date of first ART drug dispensation. ART start dates were
included through the study end date of September 30, 2011. Year
of enrolment was categorized into 5 groups: 2007 or earlier; 2008;
2009; 2010; or from January 1 through June 30, 2011. Additional
independent demographic variables included: sex; age at registra-
tion classified into 10 year age categories; body mass index (BMI)
within 30 days of eligibility dichotomized as less than or equal to
18.5 or higher; and self-reported occupation classified as any
current work vs. unemployment, including student or housewife
status. Healthcare service related variables included ART eligibil-
ity at initial registration and diagnosis of TB at eligibility. Time in
the pre-ART program was defined as months from initial clinic
registration to the date a patient was informed of eligibility.
For location information, Euclidean distance in kilometers (Km)
between LH or MPC clinic and patient village or Area locations
was determined using Google Earth [24]. Location information
was available for 8447 MPC (91%) and 4138 LH (85%) patients.
Statistical Analysis
Analysis was stratified by clinic, LH or MPC. Chi-square tests
determined significant differences between eligible patients who
started and those who did not, by clinic. Logistic regression models
assessed factors associated with starting ART in univariate and
multivariate models. T-tests determined significance of individual
variables; alpha was set to 0.05. Age and gender were included in
multivariate models a priori. Otherwise, significant factors at the
p,0.05 level in univariate models were included in multivariate
models. TB at eligibility, ART eligible at 1st visit, and CD4 cell
count were not included in multivariate models because of their
correlation with eligibility criteria. Analysis was conducted using
STATA 11.0 [25].
Results
At LH and MPC, respectively, 7 431 and 12 953 patients were
presumed eligible for ART between January 1, 2008 and June
30th, 2011; 4 841 LH and 9 285 MPC patients were included in
the study after removing pregnant women, transfers and other
patients with incomplete or inaccurate records (Figure 1). At LH, 3
929 (81.2%) of 4 841 eligible patients started ART before
September 30, 2011. Of 9 285 MPC patients, 7 212 (77.7%)
started ART during the study period. Baseline characteristics of
LH and MPC study patients were similar except MPC included a
larger proportion with tuberculosis and patients eligible for ART
at first visit (Table 1).
Table 2 describes differences in those who start ART and not,
by clinic. At both clinics, those under 24 years of age, eligible for
ART by CD4 criteria ,250 cells, and without TB at baseline were
less likely to begin ART. Patients who did not start ART as
compared to those who started ART were more likely to be
eligible at first visit (83.7% vs. 38.9% at LH and 92.1% vs. 53.3%
at MPC) and have less than 1 month in the pre-ART period
(85.2% vs 45.3% at LH and 93.8% vs. 57.2% at MPC). The
proportion of eligible patients who initiated ART improved over
time at MPC but decreased or remained stable at LH.
Univariate and multivariate models, stratified by clinic, are
presented in Table 3 (columns 2, 3 for LH, columns 4, 5 for MPC).
At both clinics, age plays a significant role. Patients ages 15–24
were less likely at LH (AOR 0.70; CI 0.53–0.93) and MPC (AOR
Table 1. Cont.
Lighthouse MPC
N = 4841* % N = 9285* %
Mean (SD) 8.9 (13.8) 7.4 (13.2)
Median (Range) 5.6 (4.0–9.6) 4.9 (3.9–6.5)
*unless otherwise specified;
**Through June 30, 2011;
***Included in WHO 3 or WHO 4.
doi:10.1371/journal.pone.0050871.t001
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(N = 7,212) p-value
Sex 0.81 0.00
Female 51.6 51.2 55.8 50.9
Male 48.4 48.8 44.2 49.1
Age group 0.00 0.00
15–24 14.9 8.9 15.9 9.3
25–34 47.2 42.7 47.1 44.5
35–44 25.8 33.1 24.8 30.6
$45 12.2 15.3 12.2 15.6
Employment 0.00 0.00
Any 75.1 68.9 76.0 79.4
None 24.9 31.1 23.9 20.6
BMI (Kg/h2) 0.01 0.03
,18.5 9.0 11.9 19.9 22.1
$18.5 91.0 88.1 80.1 77.9
Eligibility criteria 0.00 0.00
CD4#250+ Stage 1&2 55.8 40.4 49.2 30.8
WHO Stage 3 28.3 39.9 39.8 56.2
WHO Stage 4 15.9 19.7 11.0 13.1
TB diagnosis at eligibility* 0.01 0.00
Yes 2.9 5.1 10.6 28.3
No 97.1 94.9 89.4 71.7
ART eligible at first visit 0.00 0.00
Yes 83.7 38.9 92.1 53.3
No 16.3 61.1 7.9 46.7
Months in pre-ART 0.00 0.00
0–1 85.2 45.3 93.8 57.2
.1–3 3.5 25.6 3.3 20.0
.3–6 1.1 5.9 0.8 8.6
.6–12 1.0 4.1 0.6 4.4
$12 9.3 20.2 1.5 9.8
Year of registration% 0.00 0.00
#2007 10.4 89.6 3.8 96.2
2008 19.7 80.3 26.6 73.4
2009 21.6 78.4 24.5 75.5
2010 17.9 82.1 20.6 79.4
2011þ 22.3 77.7 14.3 85.7
Year of eligibility% 0.05 0.00
2008 17.9 82.1 26.8 73.2
2009 21.2 78.8 24.9 75.1
2010 17.4 82.6 19.5 80.5
2011þ 18.6 81.4 12.9 87.1
Distance from clinic (Km) 0.12 0.04
,10 km 81.5 78.9 87.1 85.1
$10 km 18.5 21.0 12.9 14.9
Distance from clinic (Km) 0.02 0.49
0–2.49 12.3 8.7 9.4 9.1
2.5–4.99 17.7 20.5 42.9 42.0
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0.70; CI: 0. 0.59–0.84) to start ART while older patients, 35–45
years, were more likely to start at both LH (AOR 1.41; CI: 1.16–
1.77) and MPC (AOR 1.22; CI: 1.06–1.40) than those ages 25–34
years. At both clinics, eligibility criteria were significantly
associated with starting ART. Both LH patients in WHO stage
3 (AOR 5.14; CI: 4.12–6.36) or WHO stage 4 (AOR 4.99; CI:
3.82–6.51) and MPC patients in WHO stage 3 (AOR 14.1; CI:
11.9–16.6) or WHO stage 4 (AOR 11.9; CI: 973–14.8) were more
likely to start than those eligible by CD4. At both clinics, time in
pre-ART dramatically increased the odds of starting ART.
Patients with 1–3 months in pre-ART were more than 28 (AOR
28.9; CI: 19.29–43.52) and 49 times (AOR 49.0; CI: 36.9–65.2)
more likely at LH and MPC, respectively, to start ART than
patients with less than one month in the pre-ART period. Patients
with a year or more time in the pre-ART period at LH (AOR
12.69; CI: 7.15–23.0) and MPC (AOR 63.2; CI: 36.4–115.2) were
also more likely to start ART than their peers with little pre-ART
time. Distance was only included in the multivariate model at LH.
LH patients who lived between 2.5–5 km (AOR 1.54; CI 1.12–
2.16) were more likely to start ART than patients who lived closer.
Discussion
Overall, 18.8% of LH and 22.4% of MPC patients informed of
their ART eligibility still failed to start ART, similar to recent
studies from Northern [26] and Southern [11] Malawi. Among
demographic factors, the odds of starting ART were lowest among
patients ages 15–24 and highest among patients older than 35
years. TB co-infection at eligibility, a WHO stage 3 condition,
increased the likelihood of starting ART at both clinics. In
multivariate models, patients eligible for ART based on WHO
stage 3 or 4 were much more likely to start than patients with
WHO stages 1–2 combined with CD4 criteria at both clinics.
Increasing months in pre-ART dramatically increased a patient’s
likelihood of ART initiation: patients with 1–12 months in the pre-
ART period were at least 11 times more likely to start ART than
their peers with less than a month in pre-ART. Lastly, distance
from clinic LH increased the likelihood of starting ART at LH for
some patients, but distance was not a significant influence at MPC.
Previous research helps illuminate the findings.
First, we found pre-ART care, the time between ART
registration and determination of ART eligibility, is the most
significant predictor of starting ART among eligible patients.
Patients who were immediately eligible at initial registration had
lower odds of starting ART at both LH and MPC. However,
patients who spent between 1–3 months in the pre-ART period
were more than 28 times at LH and 49 times at MPC more likely
to start ART, an effect that decreased slightly, but remained highly
significant, even after more than 12 months in that transitional
time. The larger effect of time in pre-ART at MPC over LH may
be due to the location of MPC near a large hospital and transit
center. Although MPC may see more patients due to easier access
to services, more of those patients may be mobile and less
prepared to start treatment thus increasing the effect of additional
pre-ART time. We acknowledge that some eligible patients may
have started ART elsewhere [13,27,28], died before they could
initiate ART [9,26,27,29,30], or simply not wanted to start ART
[31]. However, our finding that pre-ART time increases the
likelihood of ART initiation is consistent with regional findings on
the individual- and service-level factors that influence patient
retention during this period. Studies from Uganda [32] and
Malawi [33] suggest that ART uptake is influenced by patient
acceptance of their HIV-positive status, disclosure, and prepara-
tion for ART initiation. Among healthcare factors, patients from a
South African clinic who returned for one or more routine, pre-
ART visits had multiple exposures to care providers who appeared
to increase patient motivation and refute prevalent myths about
ART, ultimately reducing delays in ART initiation [34]. A study
from Kenya found that provision of other pre-ART services,
including bi-annual CD4 testing and free prophylaxis therapy,
reduced pre-ART attrition [35].
Second, as other studies from the region [13] and Malawi [26]
note, healthier patients may not perceive the need to start ART.
Both at LH and at MPC, patients who were younger, had higher
BMI, or eligibility based on CD4, possibly reflecting better health,
were less likely to start ART than those who were older, with lower
BMI or eligible by WHO stages 3 or 4. Among younger and
healthier patients, perceptions of health and wellness may combine
with lack of preparation to start lifelong ART, adding additional
barriers to ART initiation. Also, in contrast to studies that found
increased barriers to ART initiation among TB co-infected
patients [4,36], including in our own clinic [37], we found that
TB co-infection at eligibility increased the odds of starting ART.
Although both LH and MPC provide TB treatment, a stronger,
positive effect of TB co-infection at eligibility on ART initiation
was evident at MPC, a purposefully integrated clinic that also
serves as a national TB diagnosis, treatment, and follow-up facility.
Possibly, sicker patients with easy access to comprehensive TB/
ART care may be more likely to initiate ART, suggesting an
additional benefit of service integration.
Furthermore, although socio-economic factors likely contribute
to attrition among pre-ART patients, the two socio-economic










(N = 7,212) p-value
5–9.99 51.5 49.7 34.7 34.1
10–49.99 17.6 19.6 12.4 14.2
50–100 0.5 0.8 0.2 0.3
.100 0.4 0.6 0.4 0.4
Results from chi-square tests of associations within clinic.
þThrough June 30, 2011;
%row percentages.
*Included in WHO 3 or WHO 4.
doi:10.1371/journal.pone.0050871.t002
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Table 3. Results from univariate and multivariate logistic regression models assessing risk factors associated with starting ART vs.


































































1.00 1.00 1.00 1.00
























































































Starting ART among Eligible Patients
PLOS ONE | www.plosone.org 7 November 2012 | Volume 7 | Issue 11 | e50871
status, were less influential than anticipated. Previous research
from public clinics in the region noted transportation costs as a
barrier to returning for subsequent visits [13,26,30,32,38,39,40].
However, findings from this study suggest that employment and
distance to clinic were not significant deterrents to ART initiation.
Several factors may make our clinic cohorts different. First, LH
was the first public clinic providing ART and serves as a center of
excellence for the region; patients who started there may continue
to seek care there despite transportation costs or distances. At
MPC, distance may play a lesser role because of its heightened
accessibly next to the bus station in the central business district.
Moreover, lingering stigma, perceived or experienced, may still
motivate patients to seek care far from their neighborhoods and
nearby clinics. Lastly, it is possible that patients who took initiative
or had resources to seek care from more distant places were also
those more driven to continue care and initiate treatment.
These findings should be considered within the following
limitations. First, patients who were eligible earlier in the study
period had more time to start ART; some patients who became
eligible closer to July 1, 2011 may have started ART after the
study censure date of September 30, 2011. However, almost 70%
of LH and MPC patients start ART within 2 weeks of eligibility,
with median days between eligibility and ART start of 19 days and
21 days at LH and MPC, respectively, reducing the effect of this
potential bias. Second, this study used only routine service
statistics; other social, economic, or structural data was not
available. Third, pre-ART data over multiple visits is not stored.
Therefore, the number and type of visits between initial
registration and eligibility cannot be determined, decreasing our
ability to determine what service factors and visit frequency may
be influential during that period. Fourth, patients who left pre-
ART care before they were informed of their eligibility, a factor
more likely to affect those who needed to return for at least one
additional visit to receive CD4 results, were not included. Program
attrition among patients who drop out of care earlier, including
those not informed of their eligibility, merits further attention.
Lastly, several groups of patients were excluded from this analysis
(Table 1), including children, pregnant women, and those with
incomplete data such as transfer-in patients, decreasing the sample
size and reducing generalizability to other populations or clinics.
Analysis of eligible patients who were excluded compared to those
included [not shown] indicated that excluded patients at both LH
and MPC were significantly different in sex, age, eligibility criteria,
time in pre-ART, and starting ART; therefore, caution must be
used in generalizing these results especially to transfer patients who
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AOR – adjusted odds ratio from multivariate models adjusted for all other included factors.
*p,0.05;
**p,0.01,
***p,0.001. 95% CI presented in parenthesis.
þThrough June 30, 2011;
doi:10.1371/journal.pone.0050871.t003
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respectively. Despite these limitations, LH and MPC are large,
well-established, urban providers of public services, and informa-
tion on the drivers and deterrents of program attrition among
identified, ART- eligible patients is likely representative of similar
groups of eligible, urban patients in Malawi.
Conclusion
The findings suggest several steps to reduce program attrition
during this period at both Lighthouse clinics and in Malawi. First,
as those with more time between registration and eligibility appear
more likely to start. Therefore, testing and referral process that
encourage early entry into pre-ART care coupled with improved
counseling on both ART preparedness and transiting to lifelong
treatment may decrease attrition. Second, pre-ART counseling
guidelines should be revisited to resonate with those who are
eligible by CD4 and younger patients, many of whom may not feel
sick. Third, those eligible by CD4 appear less likely to start due, in
part, because they have to return to be informed of eligibility.
Implementation of point of care CD4 testing as tested in
neighboring countries may prove beneficial to reduce ART
initiation delays [41,42]. Lastly, although LH and MPC have a
successful client follow-up program for patients on ART [43], this
program should be extended to include pre-ART patients in this
clinic setting and throughout Malawi, where possible. Adoption of
one or more of these recommendations may help reduce
systematic weaknesses in the continuum of HIV-related services,
move more eligible patients swiftly onto ART, and improve
patient health and outcomes over time.
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